PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
These metrics indicate whether the stock trades cheaply or expensively relative to its fundamentals. Value investors use them to find mispricings—buying stocks that appear undervalued, with solid long-term prospects and limited downside risk.
-100.24
Negative P/E while Drug Manufacturers - Specialty & Generic median is 0.37. Seth Klarman would scrutinize path to profitability versus peers.
14.12
P/S near Drug Manufacturers - Specialty & Generic median of 13.90. Charlie Munger would examine if similar pricing reflects similar economics.
1.13
P/B 50-90% of Drug Manufacturers - Specialty & Generic median of 2.19. Mohnish Pabrai would examine if this discount presents opportunity.
-23.58
Negative FCF while Drug Manufacturers - Specialty & Generic median P/FCF is -14.12. Seth Klarman would investigate cash flow improvement potential.
-29.46
Negative operating cash flow while Drug Manufacturers - Specialty & Generic median P/OCF is -8.19. Seth Klarman would investigate operational improvement potential.
1.13
Fair value ratio 50-90% of Drug Manufacturers - Specialty & Generic median of 2.19. Mohnish Pabrai would examine if this gap presents opportunity.
-0.25%
Negative earnings while Drug Manufacturers - Specialty & Generic median yield is 0.01%. Seth Klarman would investigate path to profitability.
-4.24%
Negative FCF while Drug Manufacturers - Specialty & Generic median yield is -0.19%. Seth Klarman would investigate cash flow improvement potential.